Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Receives Hong Kong Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cells
Further expands global patent estate for capturing and detecting rare cells of interest, including CTCs, to aid in the treatment of patients with cancer SAN DIEGO , Nov. 9, 2020 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of molecular diagnostic assays, products
View HTML
Toggle Summary Biocept Awarded Broad Japanese Patent for the Use of Binding Entities in Combination with any Solid Surface to Capture and Detect any Target of Interest, including CTCs, from any Sample Type
Biocept further expands its patent estate for capturing and detecting target cells of interest, including CTCs SAN DIEGO , Nov. 5, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests, products and services designed to provide physicians
View HTML
Toggle Summary Biocept to Release Third Quarter 2020 Financial Results and Host Investor Conference Call on November 12, 2020
SAN DIEGO , Nov. 4, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating cancer patients, announces that it will release financial results for the three and nine months ended September 30, 2020 after the
View HTML
Toggle Summary Biocept Provides Update on COVID-19 Testing with More than 80,000 Samples Received
SAN DIEGO , Oct. 29, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an update on its COVID-19 testing with more than 80,000 samples received to date for processing
View HTML
Toggle Summary Biocept Appoints Samuel D. Riccitelli to its Board of Directors
Diagnostic industry veteran plans immediate start SAN DIEGO , Oct. 21, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services, announces the appointment of Samuel D. Riccitelli to its Board of Directors, effective immediately. 
View HTML
Toggle Summary Biocept Provides Update on COVID-19 Testing with More than 50,000 Specimens Received
SAN DIEGO , Oct. 6, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces it has received more than 50,000 COVID-19 specimens to date for processing through its RT-PCR
View HTML
Toggle Summary Study Shows Biocept's Target Selector™ May Provide a More Robust Method for Detecting Lung Cancer Metastasis in Cerebrospinal Fluid than Cytology
SAN DIEGO   , Oct. 5, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating cancer patients , announces results from a prospective study comparing its Target Selector™ cerebrospinal fluid testing to
View HTML
Toggle Summary Biocept to Present Study Results from Target Selector™ Testing in the Cerebrospinal Fluid of Patients with Lung Cancer at the IASLC Liquid Biopsy Meeting
SAN DIEGO , Oct. 1, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces the upcoming presentation of
View HTML
Toggle Summary Biocept Announces the Award of Japanese Patent for Primer-Switch Mutation Detection and Amplification Improvement Platform Used to Detect Rare Cell Mutations in Tissue, Blood and Cerebrospinal Fluid
Further expands Company's patent portfolio in pursuit of worldwide intellectual property protection for Primer-Switch technology for the field of oncology SAN DIEGO , Sept. 23, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to
View HTML
Toggle Summary Biocept Announces that Highmark Has Made a Positive Coverage Determination on Target Selector™ Liquid Biopsy
Two-year evaluation in advanced lung cancers at Allegheny Health Network demonstrated improved access to optimal treatment while reducing healthcare costs SAN DIEGO , Sept. 21, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to
View HTML